Terms: = Skin cancer AND PBRM1, BAF180, 55193, PB1, MGC156156, MGC156155 AND Treatment
4 results:
1. The immune response-related genomic alterations in patients with malignant melanoma.
Li L; Xiang T; Li X
Medicine (Baltimore); 2024 Apr; 103(17):e37966. PubMed ID: 38669390
[TBL] [Abstract] [Full Text] [Related]
2. ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma.
Fukumoto T; Lin J; Fatkhutdinov N; Liu P; Somasundaram R; Herlyn M; Zhang R; Nishigori C
J Invest Dermatol; 2021 Jun; 141(6):1564-1572.e4. PubMed ID: 33333124
[TBL] [Abstract] [Full Text] [Related]
3. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.
Pan D; Kobayashi A; Jiang P; Ferrari de Andrade L; Tay RE; Luoma AM; Tsoucas D; Qiu X; Lim K; Rao P; Long HW; Yuan GC; Doench J; Brown M; Liu XS; Wucherpfennig KW
Science; 2018 Feb; 359(6377):770-775. PubMed ID: 29301958
[TBL] [Abstract] [Full Text] [Related]
4. The influence of STAT5 antisense oligodeoxynucleotides on the proliferation and apoptosis of selected human cutaneous T-cell lymphoma cell lines.
Baśkiewicz-Masiuk M; Walczak M; Grzegrzółka R; Rogowska D; Machaliński B
Arch Dermatol Res; 2006 Apr; 297(10):450-8. PubMed ID: 16502315
[TBL] [Abstract] [Full Text] [Related]
